Bernie Zeiher

Trained as a pulmonary and critical care physician, he has led the development of products in critical care, pain, immunology, and infectious diseases. He was involved in and oversaw the approval of over 15 products. He is passionate about addressing unmet patients’ needs in underserved and severe diseases. Dr. Zeiher has held increasing leadership and executive responsibility positions at Astellas, Pfizer and Lilly, including board memberships, CMO and President of Development.

Dr. Zeiher received his Doctor of Medicine from Case Western Reserve University School of Medicine and a Bachelor of Science in Biology from the University of Toledo.

Suggested For You

perspectives

October 8th, 2024

Diversity Action Plan Guidance Part I: Implications for Sponsors

webinar

October 22nd, 2024

Optimal Strategies to Protect Commercially Confidential Information (CCI) in Clinical Documents and Report Trial Results Under Revised EU-CTIS Transparency Rules

perspectives

September 30th, 2024

Meet the Leaders Driving MMS’s European Growth

perspectives

September 30th, 2024

The Future of Data Management and Biostatistics: Trends and Technologies Shaping the Industry

perspectives

September 24th, 2024

Embracing Quality Management Maturity (QMM) at the Cornerstone of the Pharmaceutical Industry

perspectives

September 11th, 2024

From Historical Precedent to Modern Approvals: Lessons Learned on OTC Drug Products for FDA OMORs

webinar

September 26th, 2024

Regulatory Pathways for Nonprescription Drugs: A Deep Dive into OTC Monograph Reform and FDA Guidance

perspectives

September 4th, 2024

Email Security – Navigating Through the Process of Validation and Compliance with Healthcare Business Stakeholders

perspectives

August 27th, 2024

Optimizing Oncology Drug Development: FDA Expedited Pathways, Real-Time Review, and Global Programs

regulatory intelligence

August 27th, 2024

Recent Guidance on Diversity Action Planning

regulatory intelligence

August 26th, 2024

Oncology Programs at the FDA

regulatory intelligence

August 26th, 2024

Three Key Take Reflections on the Recent Donanemab Approval